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Introduction
Staphylococcus aureus (S. aureus) is a feared and versatile pathogen. On the one hand this microorganism innocuously colonizes 30-70% of the healthy population [1] , but on the other hand it can cause devastating invasive infections. As one of the most important sources of bacteremia and infective endocarditis, S. aureus is currently the most deadly infectious agent in the developed world [2] .
Millions of years of co-evolution between S. aureus and the mammalian immune system have led to a delicate equilibrium, where the slightest imbalance can lead to either clearance of bacterial colonization or destruction of the host. It is still not clear how our immune system is able to control S. aureus, but it seems to rely more on innate than acquired immunity, as illustrated by the failed attempts to develop a protective vaccine [3] .
In recent years, it has become clear that the coagulation system is a vital part of innate immunity. Invading pathogens, or tissue damage, trigger an inflammatory response and in parallel activate the coagulation cascade. Innate immune cells release several procoagulant molecules such as tissue factor and degrade natural anticoagulants. Activated neutrophils form neutrophil extracellular traps (NETs) by extruding their DNA in response to bacterial pathogens. Together with polyphosphates released by bacteria these NETs are potent activators of the contact activation pathway [4] [5] [6] . Activation of the coagulation cascade will eventually lead to the generation of thrombin, which converts fibrinogen into insoluble fibrin strands and activates platelets, thereby forming a blood clot. This coagulum can seal off an infection and prevents further bacterial spreading [5] [6] [7] [8] . After containing an infection, fibrin serves as a scaffold for platelets and white blood cells, thereby further propagating an inflammatory response to eliminate the intruder [9, 10] . This strong entanglement of the hemostatic system and innate immunity, referred to as immunothrombosis, is exemplified by the frequent thrombotic or hemorrhagic complications in severe infections [4] .
However, as part of the evolutionary arms race, for every immune defense mechanism, S. aureus has developed an effective countermeasure. Armed to the teeth with virulence factors, it harbors an extensive arsenal of ways to manipulate the hemostatic system. In this review, we describe how S. aureus manipulates coagulation and how this affects the outcome of the two most deadly S. aureus infections: sepsis and infective endocarditis.
In bacteremia and sepsis, S. aureus gains access to the bloodstream. Activation of coagulation will then either aid in clearing the infection or spiral out of control leading to disseminated intravascular coagulation (DIC). In infective endocarditis, bloodborne bacteria adhere to the damaged or inflamed endothelium of the cardiac valves, after which they become embedded in a matrix of fibrin and platelets. Sealed from the immune system, S. aureus can grow unhindered, forming an ever-growing infected thrombus, which will ultimately embolise or obstruct and destroy the heart valves [11] .
S. aureus coagulases: uncontrolled fibrin generation
Its ability to coagulate blood is one of the most discernable features of S. aureus and separates it from the less virulent coagulase-negative staphylococci. S. aureus bypasses the tightly regulated coagulation cascade and directly activates thrombin by secreting two coagulases: staphylocoagulase (Coa) and von Willebrand factor binding protein (VWbp) [12, 13] .
The coagulation cascade generates thrombin by proteolysis. The prothrombinase complex cleaves prothrombin between Arg15 and Ile16. This creates a new N-terminus, which inserts into the activation pocket of thrombin, inducing a conformational change that leads to enzyme activation. In contrast, the coagulases do not act by proteolytic cleavage, but form a tight stoichiometric complex with prothrombin. Once bound, they insert their own N-terminal amino acids, resembling those of cleaved thrombin, into the activation pocket. The resulting complex of Coa or VWbp bound to prothrombin is referred to as staphylothrombin and is fully capable of converting fibrinogen into fibrin [14] (Fig. 1) .
Coa contains the N-terminal a-helical D1-D2 domains, which are responsible for binding and activating prothrombin. They are followed by a 153-residue linker region and finally by a C-terminal R-domain [15] . This R-domain has high affinity for fibrin(ogen) and consists of several 27-amino acid repeats. The number of repeats varies between Coa molecules of different strains and each repeat is capable of binding a molecule of fibrinogen [16] . Binding to fibrin strands confines staphylocoagulase to the site of infection, as the secreted molecule would otherwise diffuse. This was illustrated in an endocarditis mouse model where staphylothrombin remained confined to the growing thrombotic vegetation [17] .
VWbp shares the prothrombin-activating D1-D2 domains at its N-terminus with staphylocoagulase but lacks further resemblance. Its C-terminal instead contains binding regions both for von Willebrand factor (VWF) and fibrinogen. However, VWbp has significant lower affinity for fibrinogen than staphylocoagulase and lacks the multiple fibrinogen binding C-terminal repeat domains of staphylocoagulase [18] This explains why in soft tissue infections, staphylocoagulase remains located close to the bacteria, creating a tight fibrin layer around the S. aureus colonies, whereas VWbp is more dispersed and responsible for a larger fibrin meshwork surrounding the capsule [18, 19] . Nevertheless, part of VWbp remains bound to the cell wall, allowing it to double as an adhesin for VWF (see below). Interestingly, VWbp is anchored to the cell wall by the fibrinogen binding protein clumping factor A (ClfA). ClfA might therefore help in delivering fibrinogen to staphylothrombin. [20] .
Coagulation is a double-edged sword in S. aureus infections and both the host and the pathogen will try to get control over this powerful weapon. Thrombin helps to contain an infection by capturing invading pathogens in a meshwork of fibrin strands. Transgenic mice expressing fibrinogen that is unable to polymerize are significantly hampered in their ability to clear S. aureus from the peritoneal cavity [21] . Once captured in fibrin, bacteria are an easy target for infiltrating leucocytes that dock onto the polymerized fibrin strands via the aMb2 integrin (Mac-1). Loss of the aMb2-binding motif on fibrinogen impedes clearance of S. aureus from the peritoneal cavity [10] .
However, fibrin formation can also be advantageous for the pathogen and detrimental to the host. This precious balance is illustrated by the different response of fibrinogen knockout mice to S. aureus sepsis. When bacteremia is induced by intraperitoneal injection, these mice succumb faster to the infection than wild-type mice [21] , whereas after intravenous injections of S. aureus, fibrinogen knockout mice have an increased survival [22] . Similarly, transgenic mice with only 10% of normal prothrombin levels have an increased survival after intravenous S. aureus injection [22] .
Fibrin is an essential component of in vivo-formed S. aureus biofilms and abscesses. Staphylothrombin-generated fibrin encapsulates S. aureus and provides it with shelter from the immune system and from antimicrobial treatment [23, 24] . In preclinical models, mutant S. aureus strains lacking both staphylocoagulase and VWbp were significantly reduced in their ability to cause skin infections [23, 25] , catheter infections [24] or lethal sepsis [26] . Moreover, inducing coagulase activity in the otherwise harmless Staphylococcus simulans transformed it into a pathogen that could survive in the bloodstream and cause metastatic infections [27] .
As endocarditis vegetations mainly consist of bacterial colonies embedded in fibrin and platelets [28] (Fig. 4) , one might expect an important role for staphylothrombin in forming these lesions. Early studies testing the effect of staphylocoagulase gene deletion in a rat endocarditis model could not show a reduced virulence of staphylocoagulase-deficient mutants [29, 30] . However, these studies were performed before the discovery of the second coagulase VWbp and their results might be explained by functional redundancy. Using fluorescent or radiolabeled prothrombin, Panizzi et al. could visualize high staphylothrombin activity within growing S. aureus endocarditis lesions in mice. In addition, mice infected with the double coa-VWbp mutants showed increased survival, compared with those infected with isogenic wild-type S. aureus [17] .
Because of its role in S. aureus virulence, staphylothrombin is an attractive target for therapy. As the coagulases act downstream of the coagulation cascade they are not inhibited by (low-molecular-weight) heparins, vitamin K antagonists and factor Xa-inhibitors. Moreover, the bivalent thrombin inhibitors hirudin and bivalirudin cannot bind staphylothrombin because the coagulases block exosite I. However, small molecule direct thrombin inhibitors such as dabigatran and argatroban do inhibit staphylothrombin activity [31] . Treating mice suffering from bacteremia, soft tissue or catheter infections with dabigatran improves efficacy of antibiotics and overall survival in sepsis [23, 24, 26] , whereas pretreatment with dabigatran prevents S. aureus endocarditis in rats [32] . A feasibility clinical trial investigating dabigatran as add-on to antibiotics is currently being performed [33] .
Binding of coagulation factors, turning the hemostatic system against the host In addition to Coa and VWbp, S. aureus encodes several adhesins that also modulate the activity of host clotting factors. Adhesins are cell-surface molecules that facilitate bacterial adhesion and are powerful virulence factors. They can be categorized as either proteins that are Fig. 1 . Mechanism of action of the Staphylococcusaureus coagulases. Proteolytic activation of prothrombin to thrombin is tightly controlled by the coagulation cascade. After proteolytic cleavage of the N-terminus, the newly formed N-terminal part is inserted into the activation pocket, which activates the enzymatic site. S. aureus secretes two distinct coagulases, von Willebrand factor binding protein and staphylocoagulase, which both bind to the prothrombin exosite I and activate the enzymatic thrombin site without requiring proteolysis of the prothrombin N-terminus. Because of this direct prothrombin activation, anticoagulants (depicted in red) that act upstream in the coagulation cascade, such as vitamin K antagonists, heparins or Xa inhibitors, do not affect S. aureus-mediated thrombin activity ('staphylothrombin' activity). Bivalent thrombin inhibitors such as bivalirudin (not depicted) are also ineffective, because they require the exosite I for binding to thrombin, which is blocked by the bacterial coagulase. In contrast, small molecule direct thrombin inhibitors such as dabigatran are the only anticoagulants that can block staphylothrombin activity. [Color figure can be viewed at wileyonlinelibrary.com] covalently bound to the cell wall (microbial surface components recognizing adhesive matrix molecules [MSCRAMMs]) [34] or secreted ligands that can somehow bind back to the bacterial surface (secretable expanded repertoire adhesive molecules [SERAMs]) [35] . An overview of S. aureus proteins that interact with the host's vascular biology is given in Table 1 .
The MSCRAMMs consist of up to 24 proteins, each containing an LPXTG-motif. This motif prompts covalent anchoring to the cell wall through a transpeptidase reaction mediated by the sortase A (SrtA) enzyme [36] . Although some of these proteins act as adhesins, others function in immune evasion or iron acquisition, or have unknown functions. Some authors prefer the term cell wall anchored proteins, rather than MSCRAMMs [34] .
Among these cell wall-anchored proteins are the collagen adhesin (Cna), providing binding to collagen and laminin, and the S. aureus protein A (SpA), which binds immunoglobulins and VWF (see below), but most renowned for their role in S. aureus virulence are the clumping factors ClfA and ClfB and the fibronectin binding proteins FnBPA and FnBPB.
The cell wall-anchored clumping factors
ClfA binds complement factor I and thus aids in immune evasion, but it is best known for its ability to interact with fibrinogen. ClfA binds with high affinity to the C-terminal region of the fibrinogen c-chain, by a mechanism called dock, lock and latch, and interacts with both soluble and immobilized fibrinogen, as well as with fibrin. In blood, binding to the dimeric fibrinogen molecule causes S. aureus to clump together in small aggregates, hence the name 'clumping factor'. The formation of these aggregates is then further enhanced by conversion of fibrinogen into fibrin by staphylocoagulase [26] . Within these aggregates, S. aureus is shielded from the immune system and protected from phagocytosis [37] . In addition, these aggregates are more likely to be retained in the microcirculation and thus promote metastasis of infection. In sepsis models, ClfA-deficient mutants cause less mortality and decreased metastasis [26] . Further evidence that this was mainly due to fibrinogen binding comes from transgenic mice lacking the ClfA binding motif on fibrinogen. These mice also have an increased survival in case of S. aureus sepsis [22] . Besides clumping of S. aureus, ClfA also increases its adhesion to fibrino(gen)-coated foreign bodies. It is therefore likely to promote catheter or intracardiac device infections [24] . In addition, fibrinogen bound to ClfA can also engage the a v b 3 integrin on endothelial cells, thereby bridging S. aureus to the endothelium [38] .
Because of these adhesive features, ClfA is a crucial virulence factor in S. aureus endocarditis. Endocarditis is thought to occur on either damaged or inflamed heart valves. In both instances, the valvular endothelium loses its anticoagulant properties and fibrin and platelets are deposited on the valve surface, forming precursor lesions called thrombotic non-bacterial endocarditis [11] . Using ClfA, circulating bacteria can then readily bind and infect these lesions (Fig. 4) . Several preclinical studies confirmed ClfA to be a crucial virulence factor in S. aureus endocarditis [29, [39] [40] [41] .
ClfB has significant homology with ClfA and also binds fibrin(ogen). However, although ClfA is constantly expressed, ClfB is only detectable in the early exponential phase and in smaller amounts [42] . It is therefore thought to be of only minor significance in sepsis and endocarditis [43] .
The cell wall-anchored fibronectin binding proteins Most S. aureus strains produce two homologous FnBPs: FnBPA and FnBPB. The FnBPs have N-terminal domains that are analogous to that of ClfA and therefore also bind the fibrinogen c-chain, albeit with lower affinity than ClfA. In addition to fibrinogen, the FnBP N-terminus also binds to elastin, to plasminogen and to FnBP itself, promoting S. aureus aggregation. The C-terminal region consists of tandemly repeated fibronectin-binding domains, which can bind up to nine fibronectin molecules with high affinity. As binding of fibronectin reduces the affinity of the FnBPs for fibrinogen, fibronectin binding usually predominates, because fibronectin is ubiquitously present in plasma and in the extracellular matrix [44] .In a mouse sepsis model FnBPA and FnBPB mutants were significantly less virulent than wild-type S. aureus [45] . In addition, the FnBPs facilitate the adhesion to fibronectincoated foreign bodies and therefore also promote catheter infections [46] .
Fibronectin is also abundantly present in endocarditis lesions [47] , and S. aureus mutants with deletions in FnBPA or FnBPB were less virulent in rat endocarditis models [48] . In addition, the FnBPs also play a key role in endothelial cell invasion. When the FnBPs bind, they induce a conformational change in fibronectin, exposing a previously concealed RGD motif. This integrin-binding motif is recognized by the a 5 b 1 on the surface of endothelial cells. Binding of the S. aureus-FnBP-fibronectin complex leads to a 5 b 1 clustering, which induces endocytosis. This allows S. aureus to survive intracellularly, where it is shielded from the immune system or antibiotics [49] .
The attachment to the endothelium is thought to be crucial in the development of endovascular infections. Although ClfA is key in the initial adhesion to endocarditis precursor lesions, FnBPs contribute to further disease progression. To study the contribution of individual cell wall-anchored proteins, Moreillon and coworkers used the non-pathogenic Lactococcus lactis in a rat endocarditis model. Normally, the lactococci are unable to infect the heart valves. Expression of ClfA alone allowed the bacteria to adhere to the valves and form early endocarditis lesions, but these lesions became rapidly cleared by the immune system. In contrast, lactococci expressing FnBPA not only adhered to the valves, but also invaded the adjacent endothelium and were therefore able to persist [41] . ClfA and the FnBPs thus act synergistically in the pathogenesis of endocarditis.
The secreted adhesion molecules
Besides the cell wall-anchored adhesins, many of the secreted S. aureus proteins also interact with coagulation factors. Extracellular fibrinogen binding protein (Efb) is a small (16 kD) secreted protein that binds fibrinogen on its N-terminus and complement C3 on its C-terminal end. When S. aureus becomes coated with opsonizing C3b, Efb binds the complement molecule and shields it with fibrinogen molecules, thereby preventing phagocytosis by neutrophils [50] . In addition, Efb also blocks the binding motif for the leukocyte receptor a M b 2, thereby preventing leukocytes from adhering to the fibrin capsule surrounding S. aureus [51] .
The extracellular matrix binding protein (Emp) is a little bigger (40 kDa) and binds to fibronectin, fibrinogen, collagen and vitronectin. Deletion of Emp reduces the adherence of S. aureus to fibrinogen under static conditions [52] . Emp contributes to S. aureus virulence in a murine abscess model [53] , however, its precise role in intravascular infections remains undetermined.
Lastly, the largest of the secreted fibrinogen-binding proteins is the 60-70 kDa extracellular adherence protein (Eap). Often referred to as the 'sticky protein', it interacts with prothrombin, fibrinogen, fibronectin, thrombospondin-1, bone sialoprotein, vitronectin and osteopontin. It also binds bacterial cell wall components, thereby promoting bacterial clustering. In addition, it interacts with intercellular adhesion molecule-1 (ICAM-1), bridging S. aureus to endothelial cells, while preventing neutrophil recruitment [54] . Like Efb, EAP also inhibits complement deposition [55] and causes endothelial cell activation [56] and platelet aggregation [57] . Unsurprisingly, EAP is an important virulence factor in mouse sepsis models [56] . Its role in endocarditis, however, remains to be determined.
Staphylokinase: breaking the chains that bind
The remarkably versatile S. aureus can not only create and bind blood clots, but also degrade them by activating fibrinolysis. The coagulation cascade is balanced by a fibrinolytic system, which uses plasmin to dissolve excessive blood clots. Plasmin is formed through cleavage of its precursor plasminogen by tissue-type plasminogen activator (t-PA) or urokinase (u-PA). Although fibrin is the main substrate of plasmin, it also degrades various extracellular matrix proteins, such as laminin, fibronectin and vitronectin [58] .
S. aureus can induce fibrinolysis by secreting the small 15 kDa protein staphylokinase. Staphylokinase has only weak affinity for plasminogen and cannot activate it directly, but it strongly binds to small traces of plasmin and the resulting staphylokinase-plasmin complex cleaves plasminogen and thus generates more plasmin [59] (Fig. 2) .
Most S. aureus strains express staphylokinase, which is not part of the S. aureus core genome. Instead it is contained in a pathogenicity island, which harbors other virulence factors involved in immune evasion and is carried by a bacteriophage [60] . In contrast to the coagulases, staphylokinase has a high specificity for human plasmin and is inactive in other species. This makes it difficult to study in preclinical infection models and its role as a virulence factor is less well examined.
However, it is hypothesized that staphylokinase aids in bacterial spreading and dispersal of S. aureus once the bacterial population becomes too large. Staphylokinase is under the control of the accessory gene regulator (agr), a quorum sensing mechanism that upregulates staphylokinase expression once a critical bacterial density is reached [61] . If fibrin-rich biofilms or soft tissue abscesses become too crowded, S. aureus activates plasmin to provide an escape.
First, plasminogen is captured on the bacterial surface by FnBPs [62] . Normally, the FnBPs only weakly interact with plasminogen. However, in the presence of fibrinogen this affinity increases significantly, capturing plasminogen when present in a fibrin(ogen)-rich environment [63] . The bound plasminogen is then activated to plasmin by staphylokinase, providing the bacteria with a powerful protease on its surface. This allows S. aureus to break free from a fibrin-rich biofilm [64] or spread through tissue barriers in skin or soft tissue infections [65, 66] . It is therefore plausible that staphylokinase also contributes to the breakdown and embolization of fibrin-rich vegetations in infective endocarditis, which might explain why S. aureus endocarditis vegetations are more prone to embolization.
In addition to its role in fibrinolysis, the staphylokinase-plasmin complex also promotes immune evasion by degrading opsonic molecules such as C3b or IgG [67] and antimicrobial peptides such as a-defensin [68] .
Messing with platelets: a dangerous game to play
Platelets function as the reserve of the innate immune system and are less well armed than leukocytes. Nevertheless, in the case of infection they are quickly called to arms and aid in battling invading microorganisms. Platelets are well equipped to spot intruders through an arsenal of pattern-recognition receptors, such as the Toll-like receptors (TLRs) TLR4, TLR2 and TLR9, as well as complement and immunoglobulin receptors (such as FccRIIa) [69] . In addition, inflammation will recruit additional platelets through thrombin-mediated PAR-1 and PAR-4 signaling, a IIb b 3 activation by fibrin and VWF release from activated endothelial cells.
Once arrived at the site of infection, activated platelets call for reinforcements by secreting various cytokines and chemokines to attract neutrophils and macrophages. These leukocytes can then dock on the formed platelet plug by binding of the leukocyte receptors PSGL-1 or a M b 2 to Pselectin or GPIba on platelets, respectively. Platelets stimulate leukocytes to eliminate the intruders and are crucial for the release of neutrophil extracellular traps (NETs), a mesh of extruded DNA that facilitates bacterial capture and contains antimicrobial molecules [70, 71] . In addition, platelets themselves also secrete various antimicrobial peptides [72] and can even phagocytose bacteria [73] .
Considering their importance in innate immunity, it is not surprising that S. aureus has developed multiple ways to manipulate platelets [74] . Bacteria can interact with platelets by direct binding to a platelet surface molecule, by binding a protein that also serves as a ligand for a platelet receptor, or by secreting molecules that engage platelets [74] .
When S. aureus is added to platelet-rich plasma in an aggregometer at a bacteria:platelet ratio of 1 or higher it readily induces almost complete platelet aggregation with a lag time of 2-4 minutes in most donors [75] . Most studies on S. aureus-platelet interactions assessed differences in lag time or aggregation amplitude of S. aureus mutants compared with wild-type bacteria in an aggregometer.
As the integrin a IIb b 3 (GPIIb/IIIa) is the most abundant platelet surface receptor, most S. aureus-platelet interactions involve this receptor. Fibrin(ogen), fibronectin and VWF are all capable of binding a IIb b 3 . As these proteins are also bound by several S. aureus surface proteins, they can bridge S. aureus to platelets and induce a IIb b 3 clustering and activation (Fig. 3) . S. aureus mutants deficient in ClfA, ClfB, SpA, FnBPA or FnBPB show an increased lag time in an aggregometer [76] [77] [78] [79] , whereas lactococci expressing these proteins become able to activate platelets, with the exception of SpA [78] .
To induce full aggregation, a second signal besides a IIb b 3 activation is necessary. When a mixture of washed platelets and S. aureus is supplemented with fibrinogen or fibronectin, platelet aggregation does not occur. However, when additional immunoglobulins are added, platelets become activated. Immunoglobulins bridge epitopes on the S. aureus cell wall to the platelet immunoglobulin receptor FccRIIa, which enhances a IIb b 3 signaling [76] [77] [78] 80, 81] . Only when S. aureus engages both FccRIIa and a IIb b 3 at the same time do positive feedback mechanisms, such as degranulation and secretion of ADP, TxA2 and PF4, eventually lead to full platelet aggregation [81] (Fig. 3) . The need for all these steps and feedback loops explains the observed lag time. 
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Traces of plasmin by spontaneous activation Fig. 2 . Mechanism of action of staphylokinase. Staphylokinase (SAK) binds to traces of plasmin and stabilizes the enzymatically active form. This SAK/plasmin complex can then generate more plasmin activity through auto-activation of plasminogen through plasmin, generating a positive feedback loop that results in high local plasmin activity. Besides mediating fibrin degradation, the SAK/plasmin complex also activates matrix metalloproteinases, which have a broader proteolytic spectrum and can facilitate bacterial spreading through tissues by degrading extracellular matrix. Finally, SAK/plasmin also diminishes the activity of opsonic factors, thus contributing to the arsenal of immune-evasive mechanisms of S. aureus. [Color figure can be viewed at wileyonlinelibrary.com]
In addition, because fibrin is a more potent agonist of a IIb b 3 than fibrinogen, staphylocoagulase also reinforces a IIb b 3 -induced platelet aggregation [75, 82] . Inhibiting staphylothrombin increases the lag time and blocking both staphylocoagulase activity and FccRIIa abolishes platelet aggregation. Interestingly, although thrombin can directly induce platelet aggregation through PAR-1 and PAR-4 activation, staphylothrombin could not, illustrating that it is incapable of PAR activation [75] .
Finally, several other mechanisms of S. aureus-induced platelet aggregation have been described (Fig. 3) . SpA can induce platelet aggregation by direct interaction with the platelet complement receptor gC1qR [83] , whereas the S. aureus iron-regulated surface determinant B (IsdB), another cell wall-anchored protein, engages a IIb b 3 directly [84] . Also, several secreted S. aureus toxins, such as a-toxin, b-toxin and staphylococcal superantigen-like 5, induce platelet aggregation in vitro [85] [86] [87] . Fig. 3 . Overview of interactions between Staphylococcus aureus, platelets and the endothelium. This figure illustrates some of the many mechanisms that allow S. aureus to interact with platelets, extracellular matrix proteins and coagulation factors, and the vascular wall. The redundancy of these mechanisms suggests that interactions with platelets and with the vascular wall are important contributors to S. aureus virulence. Binding to platelets is typically through the use of a bridging molecule present in the host plasma. There are various S. aureus surface receptors for fibrinogen, amongst which clumping factor A (ClfA) and the fibronectin binding proteins A and B (FnBPA/B) are the best characterized. These receptors bind to either fibrinogen or to polymerized fibrin with an even higher affinity. These receptors explain the high avidity of S. aureus for fibrin clots or sites of coagulation activation, and can also mediate platelet binding through bridging with the platelet aIIbb3 (GPIIb/IIIa) receptor. Through secretion of coagulases (see Fig. 1 ), S. aureus medicates local fibrin generation, further increasing this interaction. Although a single molecular bridge suffices for binding of resting platelets, the concomitant engagement of the platelet antibody receptor (FccRIIa) results in platelet activation. Other binding mechanisms include bridging through von Willebrand factor (VWF) and fibronectin, which are also ligands for platelet receptors. Interestingly, the main mediator of VWF binding under shear stress is the staphylococcal von Willebrand factor binding protein, which lacks a surface binding domain but binds to surface-anchored ClfA. The redundancy of receptors allows very effective binding of S. aureus to the vascular wall, either to damaged endothelium by binding subendothelial components, or to activated intact endothelium by binding exposed VWF strands and fibronectin. Furthermore, binding to the vascular wall can not only be direct, but also by binding to platelets that are recruited to sites of vascular damage. [Color figure can be viewed at wileyonlinelibrary.com] However, as most of these interactions have been studied in an aggregometer with a fairly high bacteria:platelet ratio, their relevance in the high shear stress environment of the vasculature is less clear. Indeed, during intravascular infections bacteria and platelets encounter each other in circumstances that differ significantly from those in an aggregometer. Moreover, it is not clear if S. aureusinduced platelet aggregation is beneficial or detrimental for the host. Again, this depends on the situation.
During bacteremia, the battle between platelets and S. aureus is fought in the microcirculation and platelets mainly have a protective role. In patients with S. aureus bacteremia thrombocytopenia is independently correlated with mortality [88] and mice that undergo platelet depletion have a decreased bacterial clearance and succumb faster to S. aureus sepsis [89] . In mice, circulating bacteria are normally rapidly cleared from the bloodstream, mainly by the liver. Wong et al. recently showed that platelets actively patrol the microvasculature of the liver, looking for invading pathogens. When bacteremia occurs, these platelets rapidly accumulate in the liver sinusoids as a result of VWF release. There they aid macrophages and neutrophils in clearing the infection [70] . Although platelets protect against infections, widespread platelet activation may uncontrollably trigger coagulation, culminating in disseminated intravascular coagulation (DIC).
Also, in infective endocarditis platelets have conflicting roles. Platelets are thought to facilitate initial bacterial adhesion to the valves (Fig. 4) . When bacteria bind the heart valves they are hampered by the high blood flow that gushes over the valve leaflets. This creates shear stress, which bacteria need to overcome to colonize the heart valves. In the case of endothelium disruption or inflammation, platelets overcome shear stress by binding VWF. Most endocarditis pathogens, such as S. aureus, bind and use platelets as a bridge to overcome shear stress. In a rat model of S. aureus endocarditis, inhibition of platelets by aspirin plus ticlopidine or abciximab could partially prevent endocarditis [32] .
Under shear stress, bacteria-platelet interactions are mainly driven by ClfA. In a flow chamber, S. aureus is only able to bind immobilized platelets in the presence of ClfA and fibrinogen [90] , although at higher shear rates VWF could also mediate binding [91] . Conversely, when perfused at a high shear rate over immobilized S. aureus, platelets only aggregate in the presence of fibrinogen, ClfA and IgG, again illustrating the importance of both a IIb b 3 and FccRIIa [80] .
However, the role of platelets in endocarditis is not limited to the initial adhesion. Once embedded in the newly formed vegetation, bacteria are at the mercy of the surrounding platelets. As endocarditis lesions are often devoid of white blood cells, platelets are therefore the main immune cells at the scene. By secreting platelet microbicidal peptides and other antibacterial products, they may aid in clearing the infected thrombus [69] . Platelet depletion therefore aggravates streptococcal endocarditis in rabbit or rat models [92, 93] . There are no studies on the effect of platelet depletion in S. aureus endocarditis. However, S. aureus mutants that are rendered resistant to platelet microbicidal proteins are significantly more virulent in a rat endocarditis model compared with wild-type bacteria [94, 95] . 
Going against the flow by binding von Willebrand factor
Binding to platelets provides bacteria with a first mechanism to overcome shear stress, as platelets effectively bind to VWF in high shear conditions. However, in addition to hitching platelets, S. aureus can also bind directly to VWF. In a flow chamber, S. aureus readily binds to immobilized VWF. In most ligand-receptor interactions, the binding strength is inversely correlated with shear stress. However, the binding of S. aureus to VWF strengthens with increasing shear rates [96, 97] , which suggests a shear-dependent binding similar to the interaction between platelet GPIb and the VWF A1 domain [98] . Notably, when S. aureus is perfused over activated endothelial cells, it adheres to VWF in the same stringlike pattern as is observed with platelets [96, 97] .
Two S. aureus proteins have been shown to interact with VWF: the cell wall-anchored SpA and the secreted coagulase VWbp [12, 99] . SpA is best known for its binding to the Fc region of IgG, which impedes phagocytosis and is therefore thought to be crucial in immune evasion [100] . It also binds with high affinity to the VWF A1 domain and to a lesser extent to the D'-D3 domains [101] . At static conditions or low shear rates, Spa increases the adhesion of S. aureus to endothelial cells or to the extracellular matrix [99, 101] . However, at higher flow rates, this binding affinity steadily decreases and at a shear rate of 1000 s À1 almost none of the binding by S. aureus to VWF is mediated by SpA [96] . Instead, VWbp enables the VWF binding at high shear rates, by binding in a shear-dependent manner to the A1 domain [97] . Although VWbp is a secreted molecule, it is bound to the cell wall via ClfA [20] (Fig. 3) . This shear-resistant binding of S. aureus to VWF may explain why S. aureus bacteremia is so often complicated by metastatic infections. In the case of S. aureus bloodstream infection, inflammation and widespread endothelium activation lead to increased VWF levels, while causing relative deficiency in ADAMTS-13. This results in a high amount of reactive ultra-large VWF multimeres tethered to the endothelium, to which S. aureus can bind, allowing S. aureus to slow down and invade the endothelium [97] .
Indeed, in S. aureus bacteremia patients, the VWF: ADAMTS-13 ratio is a predictor of disease severity [102] . Spa mutants have only a slightly reduced virulence in a mouse sepsis model, probably owing to its immune evasion effect [103] . However, in the high shear stress environment of the vasculature, VWbp is thought to play a more important role. In a model in which the interaction of fluorescent S. aureus with the intestinal microcirculation is measured, VWbp, and not SpA, mediates the adhesion of S. aureus to the vessel wall [97] .
As the heart valves are subjected to considerable shear forces, binding to VWF might be crucial in the initial adhesion to the valvular endothelium. Consistent with its ability to only bind in low shear conditions, Spa was of little significance in a rat endocarditis model [104] . However, the unique ability of VWbp to bind VWF in a shear-dependent manner may explain why S. aureus is so proficient in causing endocarditis compared with other pathogens. Support for this hypothesis came from a recent study on Staphylococcus lugdunensis endocarditis. S. lugdunensis is a coagulase-negative staphylococcus, but with an increased virulence, and often causes infections resembling those caused by S. aureus, including native valve endocarditis. In parallel to S. aureus, it has developed the ability to bind VWF under shear, whereas other coagulase-negative staphylococci that seldom cause native valve endocarditis, do not [105] . In a mouse model, VWF binding enables S. lugdunensis to adhere to the aortic valve and cause endocarditis [105] . A similar mechanism might be at play in S. aureus valve infections.
Conclusion
Both the immune system and invading bacteria deploy coagulation as a weapon in their battle for survival. If S. aureus gains the upper hand, this can lead to ineffective bacterial clearance, reduced antibiotic susceptibility, development of endocarditis, DIC and ultimately death. Given the increase in antibiotic resistance, interfering with virulence factors related to coagulation is therefore an attractive strategy to fight S. aureus disease.
However, there is a very delicate balance at play. Depending on the situation an intervention in hemostasis can be beneficial for some patients, but might have devastating consequences for others. This is best exemplified by the failure of recombinant activated protein C (aPC) in sepsis. Despite a benefit in preclinical and clinical studies, follow-up trials failed to show any benefits and even observed an increase in bleeding [106] . The clinical failure of aPC therefore serves as a cautionary tale regarding trying to influence the delicate balance in coagulation during infections.
Nevertheless, as we gain more and more insight into how S. aureus manipulates coagulation, we are able to arm ourselves against this worthy opponent. As the development of novel classes of antibiotics has virtually come to a halt, while antibiotic resistance is ever increasing, new therapeutic strategies to battle infections are urgently needed. Targeting the manipulation of the hemostatic system therefore holds great promise as an alternative strategy to fight S. aureus.
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